RenovoRx, Inc. (RNXT) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated March 23, 2026, reports on a private placement offering (the "Offering") closed on March 20, 2026. RenovoRx, Inc., a Delaware corporation and emerging growth company, entered into a Securities Purchase Agreement on March 17, 2026, to raise capital from 15 accredited investors or qualified institutional buyers.
Key Financial Metrics and Transaction Details
- Gross Proceeds: Approximately $10 million before deducting placement agent fees and expenses.
- Securities Issued:
- 8,438,790 shares of Common Stock.
- 2,200,000 Pre-Funded Warrants (exercisable at $0.0001 per share).
- 5,319,392 Revenue Milestone Warrants (50% warrant coverage).
- Purchase Prices:
- Institutional Investors: $0.938 per Share and related Milestone Warrant.
- Insiders (Directors/Officers/Employees): $1.0288 per Share and related Milestone Warrant.
- Transaction Costs: 5.5% commission to placement agent (Konik Capital Partners, LLC) plus up to $50,000 in expenses.
Material Changes and Terms
The Offering introduces significant new equity and warrant obligations. Key terms include:
- Registration Rights: The Company must file a resale registration statement within 30 days and use commercially reasonable efforts to have it declared effective within 30 days thereafter. Failure to meet these deadlines triggers partial liquidated damages of 2.0% per month (capped at 10%) of the investor's subscription amount.
- Milestone Warrants: These expire on the earlier of March 30, 2029, or 30 days after the Company reports at least $1.5 million in product sales revenue (excluding licensing fees and upfront milestones) for any calendar quarter. Exercise prices are $1.751 for Institutional Investors and $1.9326 for Insiders.
- Pre-Funded Warrants: Issued to investors to avoid beneficial ownership limits exceeding 4.99% or 9.99%. These do not expire and are immediately exercisable.
Outlook, Risks, and Management Commentary
The filing contains forward-looking statements regarding the use of proceeds and future obligations. The Company relies on private placement exemptions (Section 4(a)(2) and Rule 506) for the sale of unregistered securities. A primary risk identified is the potential dilution from the issuance of warrants and the obligation to pay liquidated damages if the resale registration statement is not timely filed or declared effective.
Investor Verification Checklist
- Verify the exact net proceeds after deducting the 5.5% placement agent fee and $50,000 expense cap.
- Confirm the timeline for the filing and effectiveness of the Resale Registration Statement to assess liquidated damages risk.
- Review the specific revenue definition for the Milestone Warrant trigger ($1.5 million in product sales revenue excluding licensing fees).
- Assess the immediate dilution impact of the 8.4 million shares and 7.5 million warrant shares issued.
- Check the beneficial ownership percentages of the Insiders post-offering to understand the Pre-Funded Warrant allocation.